Altravax is a privately held biopharmaceutical company focused on developing first-in-class or best-in-class products to fight infectious diseases or treat other indications. The Company currently has a robust pipeline of candidates at various stages of development, including a therapeutic vaccine for chronic hepatitis B infection and a preventive vaccine against dengue virus. [Read more...]
Our product pipeline includes a therapeutic vaccine for hepatitis B, a preventative dengue vaccine, and improved vaccines for flu and HIV-1.
Altravax is currently funded by the National Institutes of Health to apply our vaccine screening platform to several infectious disease targets.